HF Advisory Group LLC Increases Position in Pfizer Inc. $PFE

Key Points

• HF Advisory Group LLC increased its holdings in Pfizer Inc. by 25.6% in Q2, owning 137,999 shares valued at approximately $3.34 million, making it the firm's 18th largest position.
• Numerous analysts have adjusted their price targets for Pfizer, with Citigroup raising it to $26.00 and Morgan Stanley to $33.00, indicating a generally positive outlook for the stock.
• Pfizer reported a strong quarterly performance with earnings of $0.78 per share and revenues of $14.65 billion, exceeding analyst expectations and showing a 10.3% increase year-over-year.

HF Advisory Group LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 25.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 137,999 shares of the biopharmaceutical company's stock after buying an additional 28,131 shares during the quarter. Pfizer comprises about 1.3% of HF Advisory Group LLC's investment portfolio, making the stock its 18th biggest position. HF Advisory Group LLC's holdings in Pfizer were worth $3,345,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new stake in shares of Pfizer during the first quarter worth $27,000. Bayforest Capital Ltd acquired a new stake in shares of Pfizer during the first quarter worth $28,000. North Capital Inc. acquired a new stake in shares of Pfizer during the first quarter worth $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the fourth quarter worth $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 0.5%

NYSE:PFE traded down $0.12 during mid-day trading on Friday, hitting $24.03. The company had a trading volume of 86,201,583 shares, compared to its average volume of 39,901,288. The business has a fifty day simple moving average of $24.63 and a 200-day simple moving average of $24.22. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $30.43. The firm has a market capitalization of $136.62 billion, a price-to-earnings ratio of 12.78, a PEG ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period last year, the company posted $0.60 earnings per share. The firm's revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's dividend payout ratio (DPR) is 91.49%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Citigroup raised their price objective on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Berenberg Bank decreased their price objective on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a report on Thursday, May 29th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.